Zhao T, Zhang Z, Chen Z, Xu G, Wang Y, Wang F
Front Oncol. 2025; 15:1534948.
PMID: 39990690
PMC: 11842269.
DOI: 10.3389/fonc.2025.1534948.
Winden K, Ruiz J, Sahin M
Curr Opin Neurobiol. 2024; 90:102934.
PMID: 39612590
PMC: 11839335.
DOI: 10.1016/j.conb.2024.102934.
Jaafar C, Aguiar R
Proc Natl Acad Sci U S A. 2024; 121(46):e2317847121.
PMID: 39495907
PMC: 11572932.
DOI: 10.1073/pnas.2317847121.
Destefanis E, Sighel D, Dalfovo D, Gilmozzi R, Broso F, Cappannini A
NAR Cancer. 2024; 6(4):zcae040.
PMID: 39411658
PMC: 11474903.
DOI: 10.1093/narcan/zcae040.
Chen Y, Zhou Z, Chen Y, Chen D
Cell Biosci. 2024; 14(1):124.
PMID: 39342406
PMC: 11439334.
DOI: 10.1186/s13578-024-01293-7.
Single-cell mA profiling in the mouse brain uncovers cell type-specific RNA methylomes and age-dependent differential methylation.
Tegowski M, Prater A, Holley C, Meyer K
Nat Neurosci. 2024; 27(12):2512-2520.
PMID: 39317796
PMC: 11614689.
DOI: 10.1038/s41593-024-01768-3.
Hyperbaric oxygen therapy alleviates intestinal dysfunction following traumatic brain injury via mA regulation.
Yu X, Zhao W, Liu Y, Lv J, Zhong X, Huang P
Int J Med Sci. 2024; 21(12):2272-2284.
PMID: 39310263
PMC: 11413893.
DOI: 10.7150/ijms.97682.
Writers, readers, and erasers RNA modifications and drug resistance in cancer.
Chen D, Gu X, Nurzat Y, Xu L, Li X, Wu L
Mol Cancer. 2024; 23(1):178.
PMID: 39215288
PMC: 11363509.
DOI: 10.1186/s12943-024-02089-6.
Discovery of a new inhibitor for YTH domain-containing mA RNA readers.
Wang C, Zhou H
RSC Chem Biol. 2024; 5(9):914-923.
PMID: 39211476
PMC: 11353026.
DOI: 10.1039/d4cb00105b.
YTHDF1 mediates translational control by m6A mRNA methylation in adaptation to environmental challenges.
Shi Z, Wen K, Zou Z, Fu W, Guo K, Sammudin N
bioRxiv. 2024; .
PMID: 39149343
PMC: 11326287.
DOI: 10.1101/2024.08.07.607063.
mA modification plays an integral role in mRNA stability and translation during pattern-triggered immunity.
Chen T, Greene G, Motley J, Mwimba M, Luo G, Xu G
Proc Natl Acad Sci U S A. 2024; 121(33):e2411100121.
PMID: 39116132
PMC: 11331096.
DOI: 10.1073/pnas.2411100121.
Readers of RNA Modification in Cancer and Their Anticancer Inhibitors.
Li F, Li W
Biomolecules. 2024; 14(7).
PMID: 39062595
PMC: 11275166.
DOI: 10.3390/biom14070881.
Liquid-liquid phase separation in diseases.
Zhang X, Yuan L, Zhang W, Zhang Y, Wu Q, Li C
MedComm (2020). 2024; 5(7):e640.
PMID: 39006762
PMC: 11245632.
DOI: 10.1002/mco2.640.
The Prognostic and Therapeutic Potential of Fragile X Mental Retardation 1 () Gene Expression in Prostate Adenocarcinoma: Insights into Survival Outcomes and Oncogenic Pathway Modulation.
Baldi S, Amer B, Alnadari F, Al-Mogahed M, Gao Y, Gamallat Y
Int J Mol Sci. 2024; 25(13).
PMID: 39000397
PMC: 11242135.
DOI: 10.3390/ijms25137290.
Dynamic RNA methylation modifications and their regulatory role in mammalian development and diseases.
Yang W, Zhao Y, Yang Y
Sci China Life Sci. 2024; 67(10):2084-2104.
PMID: 38833084
DOI: 10.1007/s11427-023-2526-2.
Structure-Based Design of a Potent and Selective YTHDC1 Ligand.
Zalesak F, Nai F, Herok M, Bochenkova E, Bedi R, Li Y
J Med Chem. 2024; 67(11):9516-9535.
PMID: 38787793
PMC: 11181329.
DOI: 10.1021/acs.jmedchem.4c00599.
Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer.
Zhang Y, Ling Y, Zhou Y, Shi X, Shen F, Zhou J
Cancer Control. 2024; 31:10732748241256819.
PMID: 38755968
PMC: 11102699.
DOI: 10.1177/10732748241256819.
Studying mA in the brain: a perspective on current methods, challenges, and future directions.
Tegowski M, Meyer K
Front Mol Neurosci. 2024; 17:1393973.
PMID: 38711483
PMC: 11070500.
DOI: 10.3389/fnmol.2024.1393973.
The YTHDF proteins display distinct cellular functions on mA-modified RNA.
Zou Z, He C
Trends Biochem Sci. 2024; 49(7):611-621.
PMID: 38677920
PMC: 11227416.
DOI: 10.1016/j.tibs.2024.04.001.
Fragile X Messenger Ribonucleoprotein Protein and Its Multifunctionality: From Cytosol to Nucleolus and Back.
Taha M, Ahmadian M
Biomolecules. 2024; 14(4).
PMID: 38672417
PMC: 11047961.
DOI: 10.3390/biom14040399.